Join the Oncology Voice Network. Join for Free
Aspiring MSL Insight: When to Present on the Interviewing Company's Product

Aspiring MSL Insight: When to Present on the Interviewing Company's Product


Share This Article


Aspiring MSL Insight: When to Present of the Interviewing Company's Product

In our last episode, insightsspoke about having a back-pocket presentation. In this installment, he presents the counter argument to that. There are times when you have to Tin-Cup it.

The MSL presentation is a make-it or break-it variable in you job interview.

Some candidates play it safe on the presentation, and some people Tin-Cup it. Do you remember the movie Tin Cup. Well, at the end, the main character, Roy McAvoy had to decide to lay up or go for the green. And he decided to go for the green.

As you approach your presentation, you have to make a similar decision. If you have a back-pocket presentation, you can certainly present it and that would be like lay-up…not taking any unnecessary risk. Others, Tin-Cup it and go for the green by presenting on that company’s drug. It’s a high risk/high reward scenario. If you hit the perfect shot and land on the green, you’ve positioned yourself to win. But if you fail to hit it perfectly, it could spell disaster.

If you choose to go for the green, and pull it off, you show the company that you are brave and can learn new things quickly. They will probably think, “She knows the data better than we do, how could we not hire her?” But you need to know that data cold because you are going to be speaking to the experts on the drug.

How can you decide to lay up or tin cup it. That’s where you have to rely on a good recruiter, your caddy, who can help you understand if you’re playing with the lead or playing from behind. If you’re playing without a caddy, then you sense that you’re the lead candidate, Michael advises to lay up. Nail that backpocket presentation. But if you sense that you’re the long shot, Tin Cup it, go for the green - go for the win.

Was that helpful? If so, subscribe to the channel and connect with Michael on linkedin. Also, be sure to join our private LINKEDIN group called KBIC JOBS-MEDICAL AFFAIRS. Thanks

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN